---
title: T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive
  T cell therapy
date: '2025-02-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39931057/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250211171020&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia
  (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL,
  are currently used as first-line treatment. Although TKIs are effective, drug resistance
  caused by the emergence of drug-selected secondary mutations in BCR-ABL remains
  a major problem for relapse, especially in patients with compound mutations. In
  this study, we aimed to investigate potential neoepitopes derived from mutated BCR-ABL
  ...
disable_comments: true
---
BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. Although TKIs are effective, drug resistance caused by the emergence of drug-selected secondary mutations in BCR-ABL remains a major problem for relapse, especially in patients with compound mutations. In this study, we aimed to investigate potential neoepitopes derived from mutated BCR-ABL ...